dbo:abstract
|
- Asunercept (Entwicklungsname APG101) ist ein experimenteller Wirkstoff, der bis 2014 in der Behandlung von Glioblastoma multiforme (GBM) untersucht wurde. Eine Arzneimittelzulassung ist mit Stand Juli 2022 bislang nicht erfolgt. (de)
- Asunercept (INN; development code APG101) is a soluble CD95-Fc fusion protein which is in clinical development for the treatment of glioblastoma multiforme (GBM) and myelodysplastic syndromes (MDS). Asunercept has been granted orphan drug status for the treatment of GBM and MDS in the EU and the US. It has also received by the European Medicines Agency (EMA) for the treatment of GBM. (en)
|
dbo:casNumber
| |
dbo:fdaUniiCode
| |
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 8250 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:casNumber
| |
dbp:legalStatus
| |
dbp:unii
| |
dbp:wikiPageUsesTemplate
| |
dcterms:subject
| |
rdf:type
| |
rdfs:comment
|
- Asunercept (Entwicklungsname APG101) ist ein experimenteller Wirkstoff, der bis 2014 in der Behandlung von Glioblastoma multiforme (GBM) untersucht wurde. Eine Arzneimittelzulassung ist mit Stand Juli 2022 bislang nicht erfolgt. (de)
- Asunercept (INN; development code APG101) is a soluble CD95-Fc fusion protein which is in clinical development for the treatment of glioblastoma multiforme (GBM) and myelodysplastic syndromes (MDS). Asunercept has been granted orphan drug status for the treatment of GBM and MDS in the EU and the US. It has also received by the European Medicines Agency (EMA) for the treatment of GBM. (en)
|
rdfs:label
|
- Asunercept (de)
- Asunercept (en)
|
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:isPrimaryTopicOf
| |
is dbo:wikiPageRedirects
of | |
is dbo:wikiPageWikiLink
of | |
is foaf:primaryTopic
of | |